Background: Acute myeloid leukemia (AML) is the most common leukemia among the adult population and accounts for about 80% of all cases. Despite advancements in therapeutic regimens, the prognosis remains very poor, especially in the elderly population. Selinexor is a first-in-class, oral, small molecule Exportin-1 inhibitor that is being developed for the treatment of a variety of cancers, including AML. The efficacy and safety issues of selinexor in the treatment of AML are still the focus of attention. Therefore, we conducted a meta-analysis to evaluate the efficacy and safety of selinexor in the treatment of AML. Methods: According to the search strategy, regardless of publication date or language, randomized controlled trials of selinexor for AML will be retrieved from 8 databases. First of all, the literature was screened according to the eligibility criteria, and use the Cochrane Collaboration's tool to assess the quality of the included literature. Then, using Rev Man 5.3 and STATA 14.2 software for traditional meta-analysis. Finally, the evaluation of the quality of the evidence and the strength of the recommendations will adopt the Grading of Recommendations, Assessment, Development, and Evaluation method. Results: This study will evaluate the efficacy and safety of selinexor for AML, thereby providing more evidence support for clinical decision-making in AML. Conclusion: Our research will provide more references for the clinical medication of patients with AML.

Background:Acute leukemia(AL) is a modern disease, but there are records about this kind of diseases in the classical Chinese medicine books thousands of years ago. The description of yin and yang toxicosis in the classic Chinese medicine book "Jingui Yaolue" conforms to the clinical manifestations of acute leukemia. Its prescription for treating yin and yang toxicosis is Shengma Biejia Decoction. The formula contains realgar(As4S4), an important drug for the treatment of acute promyelocytic leukemia. In China, Shengma Biejia Decoction has been frequently used in the treatment of acute leukemia and has achieved excellent clinical efficacy. However, its mechanism of action is not fully clear.

No abstract

Background:Background: AML is a malignant tumor caused by changes in myeloid hematopoietic stem cells and abnormal changes in the proportion of primitive and immature myeloid cells. ZnO NPs have unique optical, chemical, electrical conductivity, antibacterial and anti-tumor properties, and are widely used in antibacterial, wound healing and tumor treatment. Mitochondria are a highly dynamic organelle that is important for many biological processes. At present, the effect of ZnO NPs on mitochondrial division and on human THP-1 cell apoptosis is still unclear. Aims:Aims: The present study aimed to elucidate the underlying mechanism of ZnO NPs induced apoptosis in acute myeloid leukemia (AML) cells by regulating mitochondrial division. Methods:Methods: The inhibitory effect of ZnO NPs on THP-1 cell proliferation was monitored by the CCK-8 method, and the

Book distributed under the Attribution-NonCommercial-NoDerivs (CC BY-NC-ND) which allows third parties to download the articles and share them with others as long as they credit the author and the Abstract Book, but they cannot change the content in any way or use them commercially.